Core Viewpoint - The emergence of a cosmetic product called "climax needle" has gained significant attention, with reports indicating a surge in demand and appointments across multiple regions. However, medical professionals express concerns regarding its safety and efficacy, highlighting the lack of scientific backing and potential risks associated with its use [2][6][12]. Group 1: Product Overview - "Climax needle" involves injecting collagen into sensitive areas within the vagina to enhance sexual pleasure and climax, with prices ranging from several thousand to tens of thousands of yuan [2]. - A primary component of the "climax needle" is Platelet-rich plasma (PRP), which is derived from whole blood and is concentrated with platelets [3][4]. - PRP has been used in medical fields like orthopedics and dentistry since around 2000, primarily for wound healing and tissue repair [4][5]. Group 2: Efficacy and Evidence - The clinical evidence supporting PRP's effectiveness in various applications, including cosmetic procedures, is limited and often based on indirect studies, with some showing negligible results compared to placebo treatments [5][10]. - Despite claims of enhancing sexual experience through PRP injections at specific points, there is no high-level evidence to substantiate these assertions, and the results may vary significantly among individuals [9][10]. Group 3: Regulatory and Safety Concerns - PRP treatments have not been officially approved for cosmetic use in China, and the current regulatory framework does not adequately cover the practices of many private medical institutions offering these services [6][16]. - There are significant risks associated with the injection procedures, including potential infections, vascular damage, and severe complications such as embolism, particularly if performed by unqualified personnel [13][15][16]. - Some institutions have previously issued guidelines prohibiting certain high-risk injection practices, reflecting ongoing concerns about patient safety in the cosmetic industry [17].